Natural COX-2 Pain Reliever Introduced as Dietary Supplement Ingredient.
Next Pharmaceuticals, Inc. has entered into an agreement with Natrol Inc., Chatsworth, California, to feature its natural, patent-pending selective COX-2 inhibitor Nexrutine in Natrol's natural pain management formula called Flexanew. Flexanew with Nexrutine will be nationally advertised early this fall with distribution throughout the U.S. in drug, grocery, mass retailers, and health food stores.
The COX-2 enzyme plays a role in inflammation and accompanying pain. Nexrutine has been shown to selectively inhibit this enzyme without any inhibition of COX-1, a stomach-protecting enzyme. "In our human trial Nexrutine was shown to be very effective yet gentle on the stomach," says Charles Kosmont, CEO of Next. "With Natrol leading the way in the natural pain management category, we expect Nexrutine to become a major dietary supplement ingredient and natural alternative for people concerned about the potential side effects of OTC anti-inflammatory/pain products."
A book by Dr. Jim LaValle titled "The COX-2 Connection" will be released this summer and features Nexrutine as the natural COX-2 inhibitor of choice. A PR campaign around the book has been scheduled, including the leading national talk radio shows.
Next is a research, development, and manufacturing company specializing in patented natural ingredients for the dietary supplement and functional food industries. In addition to Nexrutine, Next is launching a new natural patent- pending anti-anxiety ingredient called Relora(TM). "Relora has all the potential of being another blockbuster natural ingredient," says Walt Chambliss, Ph.D., Chairman of Next's scientific advisory board and Associate Director of the National Center for the Development of Natural Products, University of Mississippi. "It produces relaxation without sedation and is ideal for daytime use in our fast-paced, stressed out society."
MAKE YOUR OPINION COUNT - Click Here